EFFECT OF AN ANABOLIC STEROID (METANDIENON) ON PLASMA LH, FSH, AND TESTOSTERONE AND ON THE RESPONSE TO INTRAVENOUS ADMINISTRATION OF LRH

1976 ◽  
Vol 83 (4) ◽  
pp. 856-864 ◽  
Author(s):  
Pentti Holma ◽  
Herman Adlercreutz
Keyword(s):  
Luteinizing Hormone ◽  
Intravenous Administration ◽  
Anabolic Steroid ◽  
Plasma Levels ◽  
Oral Intake ◽  
Plasma Testosterone ◽  
Before And After ◽  
The Mean ◽  
Pre Treatment ◽  
Lh Secretion

ABSTRACT Plasma levels of testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) as well as the response of LH and FSH to the intravenous administration of 100 μg of luteinizing hormone releasing hormone (LRH) were measured in 16 well-trained athletes (mean age 30 years) before and after 2 months of daily oral intake of 15 mg of metandienon, an anabolic steroid (Anabolin®, 17α-methyl-17β-hydroxy-1,4-androstadien-3-one, Medica, Finland). All athletes continued to train regularly, just as they had done for several years. During administration of metandienon the mean plasma testosterone level fell 69%, from 29.4 ± 11.6 nmol/l to 9.1 ± 7.5 nmol/l. The mean plasma levels of LH and FSH also fell significantly (P < 0.001 and P < 0.01, respectively), both about 50%. Because LH and FSH levels were low after administration of the steroid the maximum stimulation values after LRH administration were also lower than pre-treatment values although the mean increments did not differ significantly before and after administration of the anabolic steroid. However, after treatment, the FSH response curve had a biphasic pattern in most subjects, with peaks at 10 to 20 and 50 to 60 min after the iv injection of LRH. Administration of LRH after the treatment period had no effect on FSH secretion in two subjects and no effect on LH secretion in one. Our results show that administration of an anabolic steroid causes a pronounced lowering of plasma levels of testosterone, LH and FSH but causes no gross alteration in the response of LH secretion to stimulation by LRH. The reason for the biphasic response pattern of FSH to LRH administration in most subjects is not known.

EFFECT OF GLUCOCORTICOIDS ON PLASMA TESTOSTERONE IN MEN

1978 ◽  
Vol 89 (1) ◽  
pp. 126-131 ◽  
Author(s):  
G. Schaison ◽  
F. Durand ◽  
I. Mowszowicz
Keyword(s):  
Chorionic Gonadotrophin ◽  
Human Chorionic Gonadotrophin ◽  
Plasma Testosterone ◽  
Acth Stimulation ◽  
Testosterone Levels ◽  
Before And After ◽  
The Mean ◽  
Normal Men ◽  
Lh Secretion ◽  
Dexamethasone Suppression

ABSTRACT ACTH decreases plasma testosterone levels in men. The aim of this study was to assess the part played by the glucocorticoids in this effect, and the mechanism of their action. Plasma androstenedione, testosterone, cortisol and LH were measured in 8 normal men, before and after the following tests: ACTH stimulation (2 mg im), metyrapone administration (500 mg/every 4 h/6 times) and dexamethasone suppression (8 mg/day/3 days). In addition, androstenedione and testosterone were evaluated under human chorionic gonadotrophin (5000 IU HCG/day/3 days) before and after dexamethasone suppression (8 mg/day/6 days). In all patients, ACTH decreased plasma testosterone from 5.87 ± 1.59 (sd) ng/ml to 3.06 ± 0.8 (sd) ng/ml (P < 0.001). In contrast, after metyrapone, the mean plasma testosterone was increased to 6.98 ± 1.75 (sd) ng/ml. This increase, though not statistically significant, was observed in all patients but one. Both tests resulted in a significant increase of plasma androstenedione (P < 0.01 and P < 0.001, respectively). Dexamethasone suppressed both testosterone and androstenedione levels. None of the three tests had a significant effect on the LH concentration. HCG injection increased the mean plasma testosterone to 11.46 ± 2.80 ng/ml. Dexamethasone significantly depressed (P < 0.01) the testosterone response to HCG. These data are consistent with the following conclusions: 1) The decrease of plasma testosterone levels, observed in men after ACTH administration, is not observed after metyrapone induced ACTH increase. This confirms that it is related to cortisol levels rather than to ACTH itself. 2) Glucocorticoids act directly on testicular biosynthesis since they do not induce any change in LH secretion and since dexamethasone reduces testosterone response to HCG.

THE EFFECT OF MESTEROLONE ADMINISTRATION TO NORMAL MEN ON THE PITUITARY-TESTICULAR FUNCTION

1974 ◽  
Vol 77 (2) ◽  
pp. 380-386 ◽  
Author(s):  
A. Aakvaag ◽  
S. B. Strømme
Keyword(s):  
Protein Binding ◽  
Testosterone Level ◽  
Plasma Levels ◽  
Mean Value ◽  
Plasma Testosterone ◽  
Testicular Function ◽  
Plasma Testosterone Level ◽  
Before And After ◽  
The Mean ◽  
Normal Men

ABSTRACT Mesterolone (1α-methyl-5α-dihydrotestosterone) has been given to 10 normal men, age 24–27 years, and the effect on the plasma levels of ICSH, FSH and testosterone has been studied. No effect on the plasma levels of ICSH and FSH could be detected. After 4 weeks on 75 mg mesterolone per day a significant (P < 0.01) drop in the mean value for plasma testosterone level was observed, 5.2 to 4.0 ng/ml. After another 4 weeks on 150 mg mesterolone per day a further decrease to 3.5 ng/ml was found. During mesterolone administration the protein binding of testosterone in plasma was significantly reduced, and it appeared that the level of free (non-protein bound) testosterone in diluted plasma remained unchanged, 0.37 and 0.41 ng/ml, before and after mesterolone administration respectively. The results suggest that mesterolone given in doses of 75 and 150 mg/day to normal men does not suppress the pituitary ICSH production or the testicular testosterone production.

SECRETION OF DIHYDROTESTOSTERONE BY HUMAN PROSTATE IN BENIGN PROSTATIC HYPERTROPHY

1974 ◽  
Vol 77 (2) ◽  
pp. 401-407 ◽  
Author(s):  
J. A. Mahoudeau ◽  
A. Delassalle ◽  
H. Bricaire
Keyword(s):  
Plasma Levels ◽  
Benign Prostatic Hypertrophy ◽  
Prostatic Hypertrophy ◽  
Human Prostate ◽  
Control Subjects ◽  
Peripheral Plasma ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
And Control

ABSTRACT Plasma levels of testosterone (T) and 5α-dihydrotestosterone (DHT) were determined by radioimmunoassay in 29 patients with benign prostatic hypertrophy (BPH) and in 56 control men of various ages. No significant difference was found in T, DHT nor DHT/T ratio between BPH and control subjects of similar age. Plasma DHT was higher in the prostatic than in the peripheral veins in 8/9 patients with BPH during laparotomy, indicating a prostatic secretion of DHT. No difference in the mean T nor the mean DHT was found in peripheral plasma before and after adenomectomy.

Plasma testosterone surge and luteinizing hormone beta (LH-β) following parturition: lack of association in the male rat

1995 ◽  
Vol 133 (3) ◽  
pp. 366-374 ◽  
Author(s):  
Robert F McGivern ◽  
Ralph HM Hermans ◽  
Robert J Handa ◽  
Lawrence D Longo
Keyword(s):  
Luteinizing Hormone ◽  
Cesarean Section ◽  
Gnrh Antagonist ◽  
Male Rat ◽  
Plasma Testosterone ◽  
Treatment Groups ◽  
Natural Birth ◽  
Males And Females ◽  
Lh Secretion

McGivern RF, Hermans RHM, Handa RJ, Longo LD. Plasma testosterone surge and luteinizing hormone beta (LH-β) following parturition: lack of association in the male rat. Eur J Endocrinol 1995; 133:366–74. ISSN 0804–4643 Studies examining the role of luteinizing hormone (LH) in the initiation of the postnatal surge of testosterone in the male rat have produced ambiguous results. We examined the pattern of postnatal LH secretion in the newborn male rat, coincident with plasma testosterone levels, using a specific monoclonal antibody for LH-β. In some males, we attempted to block LH secretion and the postnatal testosterone surge by injecting males with a gonadotropin-releasing hormone (GnRH) antagonist, an LH antibody or progesterone immediately after delivery by cesarean section on day 22. Following injection, animals were immediately sacrificed (time 0) or housed in a humidified incubator maintained at 30°C until sacrifice at 60, 120, 240, 360 or 480 min after delivery. Plasma from individual animals was measured subsequently for LH-β and testosterone by radioimmunoassay. Results revealed a postnatal surge of testosterone which peaked at 2 h after delivery in males from all treatment groups. This testosterone surge was not accompanied by a postnatal rise in plasma LH-β in any group. Administration of the GnRH antagonist or the ethanol vehicle produced a transient drop of approximately 25% in LH-β levels at 60 min but did not decrease the postnatal testosterone surge in the same animals. Additional studies in untreated males and females born by cesarean section or natural birth also failed to reveal a postnatal rise in plasma LH-β during the first 3 h after birth. Plasma levels in both sexes were significantly lower in animals delivered by cesarean section compared to natural birth. Overall, these results indicate that the postnatal surge of testosterone occurs without a corresponding surge of detectable LH-β in the male rat. Robert F McGivern, 6363 Alvarado Ct, Suite 200H. San Diego, CA 92120, USA

EFFECTS OF CONTINUOUS DAILY ADMINISTRATION OF 0.5 mg OF CHLORMADINONE ACETATE ON THE PLASMA LEVELS OF PROGESTERONE AND ON THE URINARY EXCRETION OF LUTEINIZING HORMONE AND TOTAL OESTROGENS

1970 ◽  
Vol 63 (4) ◽  
pp. 705-716 ◽  
Author(s):  
U. Larsson-Cohn ◽  
E. D. B. Johansson ◽  
L. Wide ◽  
C. Gemzell
Keyword(s):  
Luteinizing Hormone ◽  
Plasma Level ◽  
Urinary Excretion ◽  
Corpus Luteum ◽  
Plasma Levels ◽  
Chlormadinone Acetate ◽  
The Mean ◽  
Low Levels ◽  
The Difference ◽  
All Treatment

ABSTRACT Daily determinations of the plasma level of progesterone and the urinary excretion of luteinizing hormone (LH) and total oestrogens were performed in 6 subjects during one control cycle, immediately followed by three cycles of daily treatment with 0.5 mg of chlormadinone acetate continuously. The control cycles were ovulatory according to the parameters investigated. Two of the women showed a normal LH excretion pattern in all treatment cycles. The four other subjects also had periodical variations in the LH excretion but no distinct midcycle peaks occurred. The mean oestrogen excretion was increased in all three treatment cycles but the difference was satistically significant only in the last two cycles. Compared with the treatment cycles, the sum of progesterone values was significantly decreased in the first two cycles. Chlormadinone acetate in this dose had no thermogenic effect. Three of the subjects showed bleeding irregularities which had no clear connection with the hormone variations measured in the study. It is suggested that the low levels of progesterone might be due to a defective corpus luteum function.

OCT-Angiography as a reliable prognostic tool in laser-treated proliferative diabetic retinopathy: The RENOCTA Study

2020 ◽  
pp. 112067212096345
Author(s):  
Marco Lupidi ◽  
Ramkailash Gujar ◽  
Alessio Cerquaglia ◽  
Jay Chhablani ◽  
Daniela Fruttini ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Proliferative Diabetic Retinopathy ◽  
Additional Treatment ◽  
Post Treatment ◽  
Vascular Perfusion ◽  
Significant Difference ◽  
Before And After ◽  
The Mean ◽  
Pre Treatment ◽  
Induced Changes

Purpose: To quantitatively assess retinal neovascularizations (RNVs) in proliferative diabetic retinopathy (PDR) before and after photocoagulative laser treatment (PLT) using Optical Coherence Tomography Angiography (OCT-A). Methods: Consecutive patients with PDR were examined with fluorescein angiography (FA) and OCT-A before and after PLT. Baseline and after-treatment FA images were quantitatively analyzed to assess both the RNVs area and leakage area. On OCT-A RNVs area, vascular perfusion density (VPD), vessel length density (VLD) and fractal dimension were computed. VPD of the full-retina OCT-A underneath the RNV was determined to evaluate potential laser-induced changes in vascular perfusion. Results: Fifteen eyes of 13 patients with PDR were enrolled. The mean area of the RNVs was 0.47 ± 0.50 mm2 in the baseline OCT-A and 0.32 ± 0.40 mm2 in the post-treatment assessment ( p = 0.0002). The mean RNV VPD of RNV was 2% ± 4% in pre-treatment and 1% ± 1% for the post-treatment ( p = 0.0001). The mean VLD of RNV was 7.26 ± 1.53 at baseline and 6.64 ± 1.65 in the post treatment ( p = 0.0002). A significant difference in terms of mean RNVs area and VPD reduction between eyes that needed additional treatment and those that did not (~40% vs ~20%; p < 0.05), was observed. Mean VPD of full-retinal thickness OCT-angiogram was 55% ± 10% for the pre-treatment and 53% ± 8% for the post treatment scan ( p = 0.02). Conclusion: The quantitative OCT-A assessment of laser-induced changes of RNVs can be a useful non-invasive approach for determining treatment efficacy. A reduction of RNVs area or VPD ⩾ 40% might reveal those eyes that won’t require additional treatment. Retinal perfusion impairment seemed to progress independently from the treatment.

LUTEINIZING HORMONE (LH) AND PROGESTERONE IN PLASMA AND LH AND OESTROGENS IN URINE DURING 42 NORMAL MENSTRUAL CYCLES

1971 ◽  
Vol 68 (3) ◽  
pp. 502-512 ◽  
Author(s):  
Elof D. B. Johansson ◽  
Leif Wide ◽  
Carl Gemzell
Keyword(s):  
Luteinizing Hormone ◽  
Urinary Excretion ◽  
Plasma Levels ◽  
Luteal Phase ◽  
Maximum Level ◽  
Plasma Progesterone ◽  
Menstrual Cycles ◽  
Normal Menstrual Cycle ◽  
The Mean ◽  
Second Peak

ABSTRACT The plasma levels of luteinizing hormone (LH) and progesterone and the urinary excretion of LH and oestrogens were measured during the normal menstrual cycle of 22 young and healthy women. A total of 42 cycles were investigated. The urinary excretion of total oestrogens increased during several days before the rise of LH in the urine. The day of maximum excretion of LH and total oestrogens coincided during the midcycle period. The mid-cyclic rise in LH was found to occur on the same day in the plasma and urine and the days of maximum values coincided in 11 out of 16 cycles. In 5 cycles the maximum level was reached one day later in the urine. The plasma levels of progesterone started to increase during the LH and oestrogen peaks. The days for maximum levels of progesterone coincided with the second peak of urinary oestrogens. The levels of progesterone in the plasma reached values above 10 ng per ml in all normal cycles. The plasma levels of progesterone were below 1 ng per ml plasma when menstrual bleeding started. The length of the luteal phase was 14.4 ± 1.1 (s) days. The sum of daily urinary excretion of total oestrogens and the sum of the daily plasma progesterone levels varied within 15 per cent of the mean in five out of six women studied during more than two cycles. The variation in values for the sums of daily oestrogen excretion and plasma progesterone levels was considerably larger between menstrual cycles of different women than between menstrual cycles of the same woman.

Corticotropin- and lysine-vasopressin induced changes of plasma corticosteroids and testosterone in the adult male pig

1980 ◽  
Vol 95 (4) ◽  
pp. 518-522 ◽  
Author(s):  
W. Hahmeier ◽  
M. Fenske ◽  
L. Pitzel ◽  
W. Holtz ◽  
A. König
Keyword(s):  
Body Weight ◽  
Intravenous Injection ◽  
Intravenous Administration ◽  
The Other ◽  
Plasma Testosterone ◽  
Elevated Plasma ◽  
Other Hand ◽  
Lysine Vasopressin ◽  
Pre Treatment ◽  
Induced Changes

Abstract. Intravenous injection of 10.0 μg/kg body weight synthetic corticotropin (1-24 ACTH) into chronically cannulated boars resulted in significantly elevated plasma corticosteroid and testosterone levels between 20 and 140 min (corticosteroids) and 20–80 min (testosterone) after injection. Administration of lysine-vasopressin (LVP) at doses of 0.1, 0.2 and 0.4 IU/kg body weight elicited a significant increase of plasma corticosteroids between 20 and 40 min after injection; on the other hand, plasma testosterone concentrations tended to fall when compared to pre-treatment levels. From our results it can be concluded that exogenously applied ACTH can effectively stimulate the release of corticosteroids and testosterone. Intravenous administration of LVP results in significantly, although not maximally increased plasma corticosteroid concentrations; the release of endogenous ACTH induced by LVP injection, on the other hand, appeared to be too small to stimulate testosterone release significantly.

The use of bioimpedance spectroscopy to monitor response to treatment interventions with breast cancer-related lymphedema.

2013 ◽  
Vol 31 (26_suppl) ◽  
pp. 138-138
Author(s):  
Chirag Shah ◽  
Frank Vicini ◽  
Peter D. Beitsch ◽  
Beth Anglin ◽  
Alison Lisa Laidley ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Extracellular Fluid ◽  
Response To Therapy ◽  
Response To Treatment ◽  
Bioimpedance Spectroscopy ◽  
Post Surgery ◽  
Before And After ◽  
The Mean ◽  
Breast Cancer Related Lymphedema ◽  
Pre Treatment

138 Background: Currently, limited tools are available to assess response to therapy in patients with breast cancer related lymphedema (BCRL). The purpose of this study was to perform an exploratory analysis to determine if, in clinical settings, bioimpedance spectroscopy (BIS) can detect changes in extracellular fluid volume in response to treatment of BCRL. Methods: Three centers that had experience with BIS (L-Dex U400, ImpediMed Limited, Brisbane, Australia) provided retrospective data on 50 patients with breast cancer who were evaluated with BIS at baseline and following loco-regional procedures. Patients had a pre-surgical L-Dex measurement as well as at least 2 post-surgical measurements (before and after BCRL intervention). Decisions regarding intervention were made by physicians with no L-Dex score cut-off utilized. An analysis was performed comparing changes in L-Dex scores for those patients undergoing treatment for BCRL (n=13) versus those not undergoing intervention (n=37). A second analysis was also performed on all patients with elevated L-Dex scores compared to baseline prior to intervention (n=32). Results: The mean age was 54 years old. Fifty four percent of patients underwent SLN biopsy with a mean of 7.9 nodes removed. The mean change in L-Dex score from baseline (pre-treatment) to the first post-surgical L-Dex score measurement was 3.3 +/- 6.8. When comparing the cohort treated for BCRL to those not treated, L-Dex scores were significantly reduced (-4.3 v. 0.1, p=0.005) following intervention. For the subset of patients with elevated L-Dex scores post-surgery, the change in L-Dex score following BCRL intervention was significantly reduced (-5.8 v. 0.1, p=0.001) compared with those observed. Conclusions: These results confirm that BIS can detect increases in L-Dex scores following breast surgery and can also detect reductions in L-Dex scores following intervention for early onset lymphedema. These results demonstrate that BIS has significant clinical utility as it can be used to monitor patients with early BCRL who undergo intervention and to follow these patients (through serial measurements) to document their short and long-term response to these treatments.

PROGESTERONE-INDUCED AUGMENTATION OF PITUITARY GONADOTROPHIN RESPONSES TO LUTEINIZING HORMONE-RELEASING HORMONE IN OESTROGEN-PRE-TREATED AMENORRHOEIC WOMEN

1976 ◽  
Vol 83 (4) ◽  
pp. 684-691 ◽  
Author(s):  
Sven Johan Nillius ◽  
Leif Wide
Keyword(s):  
Luteinizing Hormone ◽  
Follicle Stimulating Hormone ◽  
Follicular Phase ◽  
Reserve Capacity ◽  
Serum Progesterone ◽  
Luteinizing Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Before And After ◽  
The Mean ◽  
Late Follicular Phase

ABSTRACT Modulating effects of oestradiol-17β and progesterone on the pituitary responsiveness to luteinizing hormone-releasing hormone (LRH) were investigated in 12 women with functional amenorrhoea. The pituitary reserve capacity for gonadotrophin section was investigated with repeated intravenous LRH tests before and after administration of oestradiol-1β followed by either progesterone or saline. Intramuscular injection of 1 mg of oestradiol-17β benzoate resulted in a suppression of both the basal gonadotrophin levels in serum and the gonadotrophin responses to LRH 24 h later. Progesterone, 25 mg im, was then administered in eleven experiments. Six h later, when the mean serum progesterone level had increased to levels similar to those seen in the early post-ovulatory phase of the menstrual cycle, there was a marked augmentation of the pituitary capacity to release both luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in response to LRH. This was not found in eight experiments where saline was given instead of progesterone after oestrogen pretreatment. These findings suggest that the greatly increased pituitary sensitivity to LRH at midcycle may be caused not only by the oestradiol increase in blood during the late follicular phase but also in part by the small pre-ovulatory rise of progesterone during the mid-cyclic LH peak. Furthermore, they add further support to the hypothesis that progesterone as well as oestradiol is involved in the induction of the LH peak at midcycle. Progesterone may be of importance to secure the release of enough LH for ovulation and normal corpus luteum formation to occur.

Sign in / Sign up

Export Citation Format

Share Document